Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679555 | 0.92 | ALDH1A1 (0.69) | ALDH1A1CYP2A6TDP1TP53RAB9A | |
| SCHEMBL14911 | 0.92 | — | — | |
| Ethylene SCHEMBL10713150 | 0.89 | ALDH1A1 (0.65) | ALDH1A1CYP2A6TDP1TP53RAB9A | |
| Charcoal, Activated SCHEMBL9462746 | 0.89 | ALDH1A1 (0.65) | ALDH1A1CYP2A6TDP1TP53RAB9A | |
| SCHEMBL30733322 | 0.89 | ALDH1A1 (0.65) | ALDH1A1CYP2A6TDP1TP53RAB9A | |
| Ethane SCHEMBL23051531 | 0.89 | ALDH1A1 (0.65) | ALDH1A1CYP2A6TDP1TP53RAB9A | |
| Hydrochloric Acid SCHEMBL9861440 | 0.89 | ALDH1A1 (0.65) | ALDH1A1CYP2A6TDP1TP53RAB9A | |
| Ammonia Solution, Strong SCHEMBL9397572 | 0.89 | ALDH1A1 (0.65) | ALDH1A1CYP2A6TDP1TP53RAB9A | |
| Hydrochloric Acid SCHEMBL9861453 | 0.89 | ALDH1A1 (0.65) | ALDH1A1CYP2A6TDP1TP53RAB9A | |
| Hydrochloric Acid SCHEMBL27666329 | 0.89 | ALDH1A1 (0.65) | ALDH1A1CYP2A6TDP1TP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275615-A1 | NOVEL SUBSTITUTED AMIDES, THEIR PREPARATION AND USE | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2011-11-10 | — | — | US | disclosed |
| US-7956093-B2 | Substituted amides, their preparation and use | ABBOTT GMBH & CO. KG (DE) | 2011-06-07 | — | — | US | disclosed |
| US-20080113989-A1 | For example, N-(1-Carbamoyl-1-oxo-3-phenylpropan-2-yl)-2-(E-2-(4-(1-pyrrolidinylmethyl)phenyl)ethen-1-yl)benzamide; calcium channel blockers; cardiovascular disorders; antiarthritic agents; inhibitors of enzymes, especially cysteine proteases such as calpain and cathepsins | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-05-15 | — | — | US | disclosed |
| US-7276500-B2 | Calcium channel blockers; cardiovascular disorders; antiarthritic agents | ABBOTT GMBH & CO. KG (DE) | 2007-10-02 | — | — | US | disclosed |
| US-6753327-B1 | NEURODEGENERATIVE DISORDER OR NEURONAL DAMAGE TREATMENT; INHIBITORS OF CALPAIN OR CATHEPSIN CYSTEINE PROTEASES; ANTIISCHEMIC AGENTS; REPERFUSION INJURIES | ABBOTT GMBH & CO. KG (DE) | 2004-06-22 | — | — | US | disclosed |
| US-20040082569-A1 | Calcium channel blockers; cardiovascular disorders; antiarthritic agents | ABBOTT GMBH & CO., KG | 2004-04-29 | — | — | US | disclosed |
| US-4111692-A | ALIPHATIC NITROGEN COMPOUND, HALOGEN COMPOUND AS FREE RADICAL GENERATOR | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275615-A1 | NOVEL SUBSTITUTED AMIDES, THEIR PREPARATION AND USE | CBR3, CBR1, HRH4 | ALDH1A1 3765/4885CYP2A6 293/4885TDP1 4196/4885 |
| US-20040082569-A1 | Calcium channel blockers; cardiovascular disorders; antiarthritic agents | CACNA1C, CACNA1E, RYR1 | ALDH1A1 3451/4885CYP2A6 1184/4885TDP1 1551/4885 |
| US-20080113989-A1 | For example, N-(1-Carbamoyl-1-oxo-3-phenylpropan-2-yl)-2-(E-2-(4-(1-pyrrolidinylmethyl)phenyl)ethen-1-yl)benzamide; calcium channel blockers; cardiovascular disorders; antiarthritic agents; inhibitors of enzymes, especially cysteine proteases such as calpain and cathepsins | CAPN1, CAPNS1, CAPN2 | ALDH1A1 1709/4885CYP2A6 2248/4885TDP1 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.